ADMA
HEALTHCAREAdma Biologics Inc
$10.08-0.17 (-1.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ADMA Today?
No stock-specific AI insight has been generated for ADMA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.21$22.37
$10.08
Fundamentals
Market Cap$2.0B
P/E Ratio14.1
EPS$0.60
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin0.3%
Debt / Equity—
Trading
Volume12.9M
Avg Volume (10D)—
Shares Outstanding232.3M
ADMA News
33 articles- ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View DownYahoo Finance·May 7, 2026
- ADMA Biologics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- High Growth Tech Stocks to Watch in the US May 2026Yahoo Finance·May 7, 2026
- Earnings Flash (ADMA) ADMA Biologics, Inc. Reports Q1 Revenue $114.5M, vs. FactSet Est of $140.0Mmarketscreener.com·May 7, 2026
- ADMA Biologics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- ADMA (ADMA) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?Yahoo Finance·May 5, 2026
- Weighing ADMA Biologics (ADMA) After A 56% One-Year Share Price DeclineYahoo Finance·May 5, 2026
- Assessing ADMA Biologics (ADMA) Valuation As Securities Investigations Follow Channel Stuffing AllegationsYahoo Finance·May 5, 2026
- Andrew Sather: Why Some Stock Buybacks Are Basically “Putting Money on Fire”247 Wall St·May 4, 2026
- ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and OlderYahoo Finance·May 4, 2026
- 3 Biotech Stocks to Watch for Respectable Growth Beyond AI247 Wall St·May 3, 2026
- Adma Biologics (ADMA) Dips More Than Broader Market: What You Should KnowYahoo Finance·Apr 29, 2026
- ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 29, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAGlobeNewswire Inc.·Apr 28, 2026
- Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a BetYahoo Finance·Apr 28, 2026
- ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 27, 2026
- Canaccord’s Support and Short-Seller Rebuttal Could Be A Game Changer For ADMA Biologics (ADMA)Yahoo Finance·Apr 27, 2026
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - LUGlobeNewswire Inc.·Apr 24, 2026
- ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 24, 2026
- ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin TrendsYahoo Finance·Apr 24, 2026
- INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer StudyYahoo Finance·Apr 23, 2026
- Kawasaki Disease Market Analysis and Global Forecast Report 2025-2035 Featuring Prominent Players - Takeda Pharmaceutical, CSL Behring, Grifols, ADMA Biologics, and OctapharmaYahoo Finance·Apr 23, 2026
- Mizuho Cuts PT on ADMA Biologics Inc. (ADMA) to $24 From $30Yahoo Finance·Apr 20, 2026
- ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 18, 2026
- ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.GlobeNewswire Inc.·Apr 10, 2026
- Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. (NASDAQ:ADMA) Investors to Contact the Firm Regarding Ongoing InvestigationGlobeNewswire Inc.·Apr 8, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAGlobeNewswire Inc.·Apr 7, 2026
- $ADMA Stock News: ADMA Biologics Investigated for Securities Fraud Following Channel Stuffing Claims – Investors Notified to Contact BFA LawGlobeNewswire Inc.·Apr 3, 2026
- ADMA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsGlobeNewswire Inc.·Mar 31, 2026
- ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman InvestigatingGlobeNewswire Inc.·Mar 28, 2026
- Securities Fraud Investigation Into ADMA Biologics, Inc. (ADMA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmBenzinga·Mar 26, 2026
All 33 articles loaded
Price Data
Open$10.16
Previous Close$10.25
Day High$10.34
Day Low$9.85
52 Week High$22.37
52 Week Low$7.21
52-Week Range
$7.21$22.37
$10.08
Fundamentals
Market Cap$2.0B
P/E Ratio14.1
EPS$0.60
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin0.3%
Debt / Equity—
Trading
Volume12.9M
Avg Volume (10D)—
Shares Outstanding232.3M
About Adma Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—